Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-14

Clinical Trial Update: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing IMCgp100 against investigator's choice in advanced uveal melanoma completed, with results posted in September 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMCgp100 (tebentafusp)

Snippet

Sponsor: Immunocore Ltd | Conditions: Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-14